Literature DB >> 32247671

The 2018 International Consensus Meeting Minor Criteria for Chronic Hip and Knee Periprosthetic Joint Infection: Validation From a Single Center.

Hussein Abdelaziz1, Kristof Rademacher2, Eduardo M Suero3, Thorsten Gehrke1, Christian Lausmann1, Jochen Salber4, Mustafa Citak1.   

Abstract

BACKGROUND: Recently, a revised definition of the minor criteria scoring system for diagnosing periprosthetic joint infection (PJI) was developed by the second International Consensus Meeting on musculoskeletal infection. The new system combines preoperative and intraoperative findings, reportedly achieving high sensitivity and specificity. We aimed to validate the modified scoring system at a high-volume center.
METHODS: We retrospectively reviewed patients who underwent a revision total hip or knee arthroplasty at our institution from May 2015 to August 2018. Serum C-reactive protein, synovial white blood cell count and polymorphonuclear percentage, leukocyte esterase test, alpha-defensin, microbiological and histologic results, and documented existence of sinus tract and intraoperative purulence were available for all patients. Cases with at least 1 major criterion were considered as infected. Using the new minor criteria, a score of ≥6 reflects PJI, while a score <3 can be considered as noninfected. Sensitivity, specificity, mean accuracy (ACC), positive predictive value (PPV), and negative predictive value (NPV) were analyzed.
RESULTS: A total of 345 cases were included. A cutoff score of ≥6 points had the following diagnostic performance: area under the curve (AUC) = 0.90; ACC = 0.88; sensitivity = 0.96; specificity = 0.84; PPV = 0.70; NPV = 0.98. Diagnostic performance was better for the hip (AUC = 0.92; ACC = 0.90; sensitivity = 0.96; specificity = 0.86; PPV = 0.81; NPV = 0.98) than the knee (AUC = 0.89; ACC = 0.85; sensitivity = 0.95; specificity = 0.83; PPV = 0.59; NPV = 0.98).
CONCLUSION: The modified scoring system proposed by the 2018 International Consensus Meeting in diagnosing PJI showed high sensitivity and a good performance, especially as rule-out diagnostic criteria. The cutoff level seems to be different between the hip and knee. Further validation studies considering the acknowledged limitations are recommended.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  international consensus meeting; minor criteria; periprosthetic joint infection; total hip arthroplasty; total knee arthroplasty; validation

Mesh:

Substances:

Year:  2020        PMID: 32247671     DOI: 10.1016/j.arth.2020.03.014

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  4 in total

1.  Comparison of dynamic and static spacers for the treatment of infections following total knee replacement: a systematic review and meta-analysis.

Authors:  Jiasheng Tao; Zijian Yan; Bin Pu; Ming Chen; Xiaorong Hu; Hang Dong
Journal:  J Orthop Surg Res       Date:  2022-07-15       Impact factor: 2.677

2.  Usefulness of serum D-dimer and platelet count to mean platelet volume ratio to rule out chronic periprosthetic joint infection.

Authors:  Ernesto Muñoz-Mahamud; Eduard Tornero; José A Estrada; Jenaro A Fernández-Valencia; Juan C Martínez-Pastor; Álex Soriano
Journal:  J Bone Jt Infect       Date:  2022-05-17

3.  Invited reply to the letter to the editor by McNally et al., 2021.

Authors:  Christian Morgenstern; Nora Renz; Sabrina Cabric; Elena Maiolo; Carsten Perka; Andrej Trampuz
Journal:  BMC Musculoskelet Disord       Date:  2021-03-08       Impact factor: 2.362

4.  Metal Artefact Reduction Sequences (MARS) in Magnetic Resonance Imaging (MRI) after Total Hip Arthroplasty (THA) : A non-invasive approach for preoperative differentiation between periprosthetic joint infection (PJI) and aseptic complications?

Authors:  André Busch; Marcus Jäger; Sascha Beck; Alexander Wegner; Erik Portegys; Dennis Wassenaar; Jens Theysohn; Johannes Haubold
Journal:  BMC Musculoskelet Disord       Date:  2022-06-28       Impact factor: 2.562

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.